Drug maker Actavis UK broke competition law by raising prices of hydrocortisone tablets by more than 12,000 percent, Britain’s competition watchdog said in a provisional ruling on Friday.
Higher prices meant the tablets cost Britain’s National Health Service (NHS) about 70 million pounds ($87 million) last year, up from about 522,000 pounds previously, the CMA said.
